[go: up one dir, main page]

ATE375980T1 - Nicotinamide und deren verwendung als p38 inhibitoren - Google Patents

Nicotinamide und deren verwendung als p38 inhibitoren

Info

Publication number
ATE375980T1
ATE375980T1 AT03704769T AT03704769T ATE375980T1 AT E375980 T1 ATE375980 T1 AT E375980T1 AT 03704769 T AT03704769 T AT 03704769T AT 03704769 T AT03704769 T AT 03704769T AT E375980 T1 ATE375980 T1 AT E375980T1
Authority
AT
Austria
Prior art keywords
inhibitors
nicotinamides
kinase
activity
mediated
Prior art date
Application number
AT03704769T
Other languages
English (en)
Inventor
Nicola Mary Aston
Paul Bamborough
Ann Louise Walker
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0203301.7A external-priority patent/GB0203301D0/en
Priority claimed from GB0225385A external-priority patent/GB0225385D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE375980T1 publication Critical patent/ATE375980T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
AT03704769T 2002-02-12 2003-02-10 Nicotinamide und deren verwendung als p38 inhibitoren ATE375980T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0203301.7A GB0203301D0 (en) 2002-02-12 2002-02-12 Novel compounds
GB0225385A GB0225385D0 (en) 2002-10-31 2002-10-31 Novel compounds

Publications (1)

Publication Number Publication Date
ATE375980T1 true ATE375980T1 (de) 2007-11-15

Family

ID=27736200

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03704769T ATE375980T1 (de) 2002-02-12 2003-02-10 Nicotinamide und deren verwendung als p38 inhibitoren
AT07117575T ATE485275T1 (de) 2002-02-12 2003-02-10 Nicotinamide und deren verwendung als p38 inhibitoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07117575T ATE485275T1 (de) 2002-02-12 2003-02-10 Nicotinamide und deren verwendung als p38 inhibitoren

Country Status (25)

Country Link
US (5) US7125898B2 (de)
EP (3) EP1864975B1 (de)
JP (2) JP4472349B2 (de)
KR (1) KR101058292B1 (de)
CN (1) CN100369898C (de)
AT (2) ATE375980T1 (de)
AU (1) AU2003207298B2 (de)
BR (1) BRPI0307351B8 (de)
CA (1) CA2474192C (de)
CO (1) CO5611147A2 (de)
CY (2) CY1107117T1 (de)
DE (2) DE60316913T2 (de)
DK (2) DK1864975T3 (de)
ES (2) ES2295553T3 (de)
IL (1) IL163090A (de)
IS (1) IS2520B (de)
MX (1) MXPA04007838A (de)
NO (1) NO327418B1 (de)
NZ (1) NZ533865A (de)
PL (1) PL212910B1 (de)
PT (2) PT1864975E (de)
RU (1) RU2309951C2 (de)
SI (2) SI1474395T1 (de)
WO (1) WO2003068747A1 (de)
ZA (1) ZA200405602B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
MXPA04007838A (es) 2002-02-12 2004-10-15 Smithkline Beecham Corp Derivados de nicotamida utiles como inhibidores p38.
GB0209891D0 (en) 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
DE602004017494D1 (de) 2003-07-25 2008-12-11 Novartis Ag Inhibitoren von p-38-kinase
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
JP4795022B2 (ja) 2003-09-30 2011-10-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環化合物を含有する新規な抗真菌剤
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
GB0402140D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402137D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402138D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
WO2006016548A1 (ja) * 2004-08-09 2006-02-16 Eisai R & D Management Co., Ltd. ヘテロ環化合物を含有する新規な抗マラリア剤
KR101225018B1 (ko) 2004-09-02 2013-01-23 쿠리스 인코퍼레이션 헤지호그 신호전달에 대한 피리딜 억제제
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
JP4874958B2 (ja) 2005-03-30 2012-02-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリジン誘導体を含有する抗真菌剤
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
US8008303B2 (en) 2005-09-16 2011-08-30 Astrazeneca Ab Biphenyl derivatives and their use in treating hepatitis C
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
DK1984338T3 (da) * 2006-01-31 2013-04-22 Synta Pharmaceuticals Corp Pyridylphenylforbindelser til inflammations- og immunrelaterede anvendelser
EP1991539A4 (de) * 2006-02-28 2010-08-25 Astrazeneca Ab Neue salze eines indolderivats und ihre verwendung in der medizin
GB0612026D0 (en) * 2006-06-16 2006-07-26 Smithkline Beecham Corp New use
RU2315040C1 (ru) * 2006-07-07 2008-01-20 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) 3-гидроксипропиламид 4,6-диметил-1н-2-оксоникотиновой кислоты, проявляющий антикоагулянтную, противовоспалительную и анальгетическую активность
US8183264B2 (en) 2006-09-21 2012-05-22 Eisai R&D Managment Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
WO2008071665A1 (en) * 2006-12-12 2008-06-19 Smithkline Beecham Corporation A nicotinamide derivative useful as p38 kinase inhibitor
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
EP2143723A4 (de) 2007-04-27 2011-05-18 Eisai R&D Man Co Ltd Salz eines heterocyclus-substituierten pyridinderivats oder kristall davon
BRPI0810202A2 (pt) 2007-05-03 2014-10-21 Pfizer Ltd Derivados de piridina
EP3034494A1 (de) 2007-08-15 2016-06-22 President and Fellows of Harvard College Heterocyclische inhibitoren von necroptose
UY31322A1 (es) * 2007-09-05 2009-04-30 Amidas heterocíclicas y sus métodos de uso-975
WO2009034390A1 (en) * 2007-09-14 2009-03-19 Arrow Therapeutics Limited Heterocyclic derivatives and their use in treating hepatitis c
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US20090281089A1 (en) * 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
US8188119B2 (en) 2008-10-24 2012-05-29 Eisai R&D Management Co., Ltd Pyridine derivatives substituted with heterocyclic ring and γ-glutamylamino group, and antifungal agents containing same
US8713459B2 (en) 2009-05-29 2014-04-29 Jason Philip Yanchar Graphical planner
CN102633715B (zh) * 2012-03-23 2014-03-26 无锡爱内特营养保健品科技有限公司 一种丝裂原蛋白激酶p38的抑制剂及其制备方法
AU2013290577A1 (en) * 2012-07-17 2015-02-26 Glaxosmithkline Llc Nicotinamide derivate in the treatment of acute coronary syndrome
WO2014060742A1 (en) * 2012-10-17 2014-04-24 Chroma Therapeutics Ltd Tert-butyl n-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2h)-yl]-3,5- difluorophenyl}ethyl]-l-alaninate or a salt, hydrate or solvate thereof
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
CN105358148A (zh) * 2013-07-10 2016-02-24 葛兰素史克知识产权第二有限公司 用于治疗肾小球疾病的losmapimod
US20170066741A1 (en) * 2014-02-19 2017-03-09 H. Lundbeck A/S 2-Amino-3,5,5-Trifluoro-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treatment of Alzheimer's Disease
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
TW201717948A (zh) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
AR105668A1 (es) 2015-08-12 2017-10-25 H Lundbeck As 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CN113149902B (zh) * 2015-09-30 2022-11-22 石药集团中奇制药技术（石家庄）有限公司 苯甲酰胺类衍生物
DE102015120397A1 (de) 2015-11-25 2017-01-05 Miele & Cie. Kg Kochfeld, insbesondere Induktionskochfeld
DE102015120409A1 (de) 2015-11-25 2017-01-12 Miele & Cie. Kg Kochfeld, insbesondere Induktionskochfeld
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
WO2018048927A1 (en) * 2016-09-12 2018-03-15 Neuralstem, Inc. Amelioration of neural deficits associated with diabetes
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
MX2020003961A (es) * 2017-10-05 2020-09-22 Fulcrum Therapeutics Inc Uso de inhibidores de p38 para reducir la expresion de dux4.
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10766854B2 (en) * 2017-10-20 2020-09-08 Sabic Global Technologies B.V. Synthesis method for the preparation of dibenzoate compounds, such as 4-[benzoyl(methyl)amino]pentane-2-yl dibenzoate
US11793741B2 (en) 2017-12-18 2023-10-24 Conopco, Inc. Topical composition
WO2019191032A1 (en) 2018-03-26 2019-10-03 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
EP4037770A1 (de) * 2019-10-04 2022-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Neuartige pyridin-2(1h)on-derivate, deren herstellung und deren verwendung zur behandlung von schmerzen
US20210300873A1 (en) 2020-03-20 2021-09-30 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
KR102298450B1 (ko) * 2021-01-29 2021-09-08 (주)프레이저테라퓨틱스 p38 MAP 키나아제 억제제로 항염증 활성을 나타내는 신규 화합물
WO2023009672A1 (en) 2021-07-27 2023-02-02 Fulcrum Therapeutics, Inc. Treatment of facioscapulohumeral muscular dystrophy with losmapimod

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822277A (en) * 1967-11-13 1974-07-02 C Dufour Certain pyridyl cyclopropylamides
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
JPS5651488A (en) 1979-10-02 1981-05-09 Meiji Seika Kaisha Ltd Penicillin derivative and its preparation
DE3332272A1 (de) * 1983-09-07 1985-03-21 Bayer Ag, 5090 Leverkusen Herbizide mittel enthaltend metribuzin in kombination mit pyridincarbonsaeureamiden
US4863940A (en) * 1984-07-26 1989-09-05 Rohm And Haas N-acetonyl-substituted amides and phytopathogenic fungicidal use thereof
EP0187284A3 (de) 1984-12-20 1987-04-15 Bayer Ag Verfahren zur Herstellung von Pyridin-carbonsäure-N-tert.-alkylamiden
DE3600288A1 (de) 1986-01-08 1987-07-16 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten
DE3605423A1 (de) 1986-02-20 1987-08-27 Bayer Ag Verfahren zur herstellung von pyridin-carbonsaeure-n-tert.-alkylamiden
DE3618004A1 (de) 1986-05-28 1987-12-03 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten
JPH01102064A (ja) 1987-10-16 1989-04-19 Ishihara Sangyo Kaisha Ltd ハロゲノピリジンカルボン酸アミド類の製造方法
DE3919348A1 (de) 1988-06-16 1989-12-21 Ciba Geigy Ag Mikrobizide mittel
MX16687A (es) 1988-07-07 1994-01-31 Ciba Geigy Ag Compuestos de biarilo y procedimiento para su preparacion.
JP2768721B2 (ja) * 1989-03-01 1998-06-25 株式会社東芝 真空バルブ用接点材料
EP0430033A3 (en) 1989-11-24 1991-09-11 Ciba-Geigy Ag Microbicidal agents
US5166352A (en) * 1991-09-12 1992-11-24 Dowelanco Pyridinecarboxylic acid chlorides from (trichloromethyl)pyridines
GB9119920D0 (en) 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DE69232003T2 (de) 1991-09-18 2002-04-25 Glaxo Group Ltd., Greenford Benzanilidderivate als 5-HT1D-Antagonisten
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
US5502194A (en) * 1992-02-19 1996-03-26 Bayer Aktiengesellschaft Process for the preparation of 2-halogeno-pyridine derivatives
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
TW240217B (de) 1992-12-30 1995-02-11 Glaxo Group Ltd
GB2273930A (en) 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
IL108630A0 (en) 1993-02-18 1994-05-30 Fmc Corp Insecticidal substituted 2,4-diaminoquinazolines
GB2276162A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benazilide derivatives
GB2276161A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benzanilide derivatives
KR100191973B1 (ko) 1993-08-31 1999-06-15 디. 제이. 우드, 스피겔 알렌 제이 5-아릴인돌 유도체
WO1995006644A1 (en) 1993-09-03 1995-03-09 Smithkline Beecham Plc Amide derivatives as 5ht1d receptor antagonists
EP0724580A1 (de) 1993-10-19 1996-08-07 Smithkline Beecham Plc Benzamilid-derivate als 5ht-1d-rezeptor antagonisten
WO1995015954A1 (en) 1993-12-07 1995-06-15 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5ht1d antagonists
GB9326008D0 (en) 1993-12-21 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9408577D0 (en) 1994-04-29 1994-06-22 Fujisawa Pharmaceutical Co New compound
EP0758330A1 (de) 1994-05-06 1997-02-19 Smithkline Beecham Plc Biehenylcarbonsäureamide verwendbar als 5-ht1d-antagoniste
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
TW397825B (en) * 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
CA2216809A1 (en) 1995-04-04 1996-10-10 Alan Naylor Imidazo[1,2-a]pyridine derivatives
GB9507203D0 (en) 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
CA2226849A1 (en) 1995-07-10 1997-01-30 Zenon Lysenko Stable polynitrile oxides and their use as curing agent especially for latex
KR100284382B1 (ko) 1995-08-22 2001-03-02 미즈노 마사루 아미드화합물 및 그의 용도
US6323227B1 (en) 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
JP2000503302A (ja) 1996-01-11 2000-03-21 スミスクライン・ビーチャム・コーポレイション 新規置換イミダゾール化合物
DE19608791A1 (de) 1996-03-07 1997-09-11 Hoechst Ag Verfahren zur Herstellung von fluorierten Aromaten und fluorierten stickstoffhaltigen Heteroaromaten
FR2754260B1 (fr) 1996-10-04 1998-10-30 Adir Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9614236D0 (en) * 1996-07-06 1996-09-04 Zeneca Ltd Chemical compounds
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5932576A (en) 1997-05-22 1999-08-03 G. D. Searle & Company 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
US6087496A (en) 1998-05-22 2000-07-11 G. D. Searle & Co. Substituted pyrazoles suitable as p38 kinase inhibitors
EP1023066A4 (de) 1997-06-13 2001-05-23 Smithkline Beecham Corp Neue pyrazole- und pyrazoline- substituierte verbindung
CA2293824A1 (en) 1997-06-19 1998-12-23 Mimi Lifen Quan (amidino)6-membered aromatics as factor xa inhibitors
US6060491A (en) 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
EP1019396A1 (de) 1997-07-02 2000-07-19 SmithKline Beecham Corporation Cycloalkyl-substituierte imidazole
ATE317845T1 (de) 1997-09-05 2006-03-15 Glaxo Group Ltd Pharmazeutische zusammensetzung, enthaltend 2,3- diaryl-pyrazolo(1,5-b)pyridazin derivate
EP1616865A1 (de) 1997-12-22 2006-01-18 Bayer Pharmaceuticals Corporation Hemmung der p38 Kinase unter Verwendung von symmetrischen und asymmetrischen Diphenylharnstoffen
JPH11218884A (ja) 1998-02-03 1999-08-10 Konica Corp ハロゲン化銀写真感光材料
DE19817461A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Benzamide, deren Herstellung und Anwendung
CN1114593C (zh) * 1998-05-08 2003-07-16 陶氏益农有限责任公司 2位被取代的吡啶的制备
MY132496A (en) * 1998-05-11 2007-10-31 Vertex Pharma Inhibitors of p38
CA2328927C (en) 1998-05-15 2008-02-19 Astrazeneca Ab Benzamide derivatives for the treatment of diseases mediated by cytokines
US6448257B1 (en) 1998-05-22 2002-09-10 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
US6867209B1 (en) 1998-05-22 2005-03-15 Scios, Inc. Indole-type derivatives as inhibitors of p38 kinase
US6130235A (en) 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
KR20010082184A (ko) 1998-08-28 2001-08-29 추후제출 p38-α 키나제의 저해체
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
AU762245B2 (en) 1998-09-18 2003-06-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
HUP0104204A3 (en) 1998-11-03 2002-06-28 Glaxo Group Ltd Pyrazolopyridine derivatives as cox-2 inhibitors, process for their preparation and pharmaceutical compositions thereof
WO2000042012A1 (en) 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US6399627B1 (en) 1999-02-11 2002-06-04 Cor Therapeutics, Inc. Inhibitors of factor Xa
WO2000052008A1 (en) 1999-02-27 2000-09-08 Glaxo Group Limited Pyrazolopyridines
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
US6509361B1 (en) 1999-05-12 2003-01-21 Pharmacia Corporation 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors
JP2003500386A (ja) 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤
AU5283900A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
CA2374820A1 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. Inhibitors of factor xa
DE19932571A1 (de) 1999-07-13 2001-01-18 Clariant Gmbh Verfahren zur Herstellung von Biarylen unter Palladophosphacyclobutan-Katalyse
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US6576632B1 (en) 1999-08-27 2003-06-10 Pfizer Inc Biaryl compounds useful as anticancer agents
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
ES2237470T3 (es) 1999-11-10 2005-08-01 Ortho-Mcneil Pharmaceutical, Inc. 2-aril-3-(heteroaril)-imidazo(1,2-alfa)pirimidinas sustituidas; y composiciones farmaceuticas y procedimientos asociados.
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
SE9904652D0 (sv) * 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MY141144A (en) 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CA2403828A1 (en) * 2000-03-22 2001-09-27 Vertex Pharmaceuticals Incorporated Inhibitors of p38
WO2001087875A1 (fr) 2000-05-18 2001-11-22 Daiichi Pharmaceutical Co., Ltd. Nouveaux derives de benzofurane
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AU2002246855B2 (en) 2000-10-23 2005-12-22 Smithkline Beecham Corporation Novel compounds
SK5402003A3 (en) 2000-11-17 2004-06-08 Bristol Myers Squibb Co Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
MXPA03008144A (es) 2001-03-09 2003-12-12 Pfizer Prod Inc Nuevos compuestos antiinflamatorios de triazolopiridinas.
AUPR399301A0 (en) * 2001-03-27 2001-04-26 Silverbrook Research Pty. Ltd. An apparatus and method(ART106)
US20020152397A1 (en) * 2001-04-06 2002-10-17 Mckay Drew Virtual investigator
ATE438615T1 (de) 2001-04-06 2009-08-15 Biocryst Pharm Inc Biarylverbindungen als serinproteaseinhibitoren
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
GB0124848D0 (en) 2001-10-16 2001-12-05 Celltech R&D Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124928D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
MXPA04007838A (es) * 2002-02-12 2004-10-15 Smithkline Beecham Corp Derivados de nicotamida utiles como inhibidores p38.
US20030225089A1 (en) 2002-04-10 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
GB0209891D0 (en) 2002-04-30 2002-06-05 Glaxo Group Ltd Novel compounds
US20060089395A1 (en) * 2002-06-10 2006-04-27 Susumu Muto Nf-kb activation inhibitors
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US20040038014A1 (en) * 2002-08-20 2004-02-26 Donaldson Company, Inc. Fiber containing filter media
US20040116479A1 (en) 2002-10-04 2004-06-17 Fortuna Haviv Method of inhibiting angiogenesis
DE10256052B4 (de) * 2002-11-30 2006-04-06 A. Raymond & Cie Abdeckvorrichtung für Montageaussparungen in den Abdeckleisten eines Fahrzeugdaches
US7136850B2 (en) * 2002-12-20 2006-11-14 International Business Machines Corporation Self tuning database retrieval optimization using regression functions
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
DE602004017494D1 (de) 2003-07-25 2008-12-11 Novartis Ag Inhibitoren von p-38-kinase
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
GB0402140D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402138D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402143D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
GB0402137D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
GB0612026D0 (en) * 2006-06-16 2006-07-26 Smithkline Beecham Corp New use

Also Published As

Publication number Publication date
EP1474395B1 (de) 2007-10-17
CO5611147A2 (es) 2006-02-28
US20100215652A1 (en) 2010-08-26
HK1113056A1 (en) 2008-09-19
CY1111083T1 (el) 2015-06-11
US20060276516A1 (en) 2006-12-07
CN1633416A (zh) 2005-06-29
US20100215661A1 (en) 2010-08-26
RU2309951C2 (ru) 2007-11-10
CA2474192C (en) 2011-06-21
NO20043176L (no) 2004-07-26
BRPI0307351B1 (pt) 2018-09-04
US20060264479A1 (en) 2006-11-23
AU2003207298A1 (en) 2003-09-04
DK1864975T3 (da) 2011-01-24
BR0307351A (pt) 2004-12-14
SI1864975T1 (sl) 2011-01-31
ES2295553T3 (es) 2008-04-16
MXPA04007838A (es) 2004-10-15
PT1864975E (pt) 2010-12-27
RU2004120553A (ru) 2005-05-27
PL372628A1 (en) 2005-07-25
HK1070896A1 (en) 2005-06-30
ZA200405602B (en) 2005-09-28
EP2258687A1 (de) 2010-12-08
US8575204B2 (en) 2013-11-05
ES2400486T3 (es) 2013-04-10
EP1474395A1 (de) 2004-11-10
IL163090A (en) 2010-06-16
EP1864975A3 (de) 2008-01-23
IS7337A (is) 2004-06-28
DE60316913T2 (de) 2008-11-20
JP2010111699A (ja) 2010-05-20
DE60334651D1 (de) 2010-12-02
US7709506B2 (en) 2010-05-04
CA2474192A1 (en) 2003-08-21
NO327418B1 (no) 2009-06-22
WO2003068747A1 (en) 2003-08-21
EP1864975A2 (de) 2007-12-12
EP2258687B1 (de) 2012-12-26
KR101058292B1 (ko) 2011-08-22
KR20040082425A (ko) 2004-09-24
CN100369898C (zh) 2008-02-20
US20050176964A1 (en) 2005-08-11
JP4472349B2 (ja) 2010-06-02
JP2005519932A (ja) 2005-07-07
ATE485275T1 (de) 2010-11-15
US7514456B2 (en) 2009-04-07
PL212910B1 (pl) 2012-12-31
BRPI0307351B8 (pt) 2021-05-25
DE60316913D1 (de) 2007-11-29
NZ533865A (en) 2006-02-24
PT1474395E (pt) 2008-01-02
EP1864975B1 (de) 2010-10-20
US8252818B2 (en) 2012-08-28
IS2520B (is) 2009-07-15
SI1474395T1 (sl) 2008-02-29
CY1107117T1 (el) 2012-01-25
DK1474395T3 (da) 2008-02-11
AU2003207298B2 (en) 2009-09-03
US7125898B2 (en) 2006-10-24

Similar Documents

Publication Publication Date Title
DE60316913D1 (de) Nicotinamide und deren verwendung als p38 inhibitoren
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
ATE517896T1 (de) P38-kinase-inhibitoren
GB0402143D0 (en) Novel compounds
ATE413392T1 (de) Kondensierte heteroyralderivate und deren verwendung als p38-kinase-inhibitoren
ATE532772T1 (de) Piperazinderivate und deren verwendung als therapeutische mittel
DE60305052D1 (de) Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
DK1603570T5 (da) Aminoheteroarylforbindelser som proteinkinaseinhibitorer
ATE537830T1 (de) Nicotinamid derivate und ihre verwendung als therapeutika
ATE420861T1 (de) 2-pyridonderivate als inhibitoren von neutrophilelastase und deren verwendung
NO20071574L (no) Arylsulfonylstilbenderivater for behandling av insomni og beslektede tilstander.
ATE466012T1 (de) Pyrazolo 3,4-b pyridinverbindungen und ihre verwendung als phosphodiesterase inhibitoren
ATE496893T1 (de) Isochinolinonderivate und deren verwendung als medikamente
GEP20074055B (en) Nicotinamide derivatives useful as pde4 inhibitors
ATE362929T1 (de) Pyridinderivate als inhibitoren der raf-kinase
ATE534649T1 (de) Imidazothiazole und imidazoxazolderivative als inhibitoren von p38
NO20062570L (no) Imidazo[1,2-A] pyridin derivater for behandling av stille gastroosofagial refluks
ATE343582T1 (de) Derivate von (6, 7-dihydro -5h-imidazo(1,2 - a)imidazol -3 -sulfonylamino)-propionamid und deren verwendung als inhibitoren der interaktion von cams und leukointreginen
PT1254905E (pt) 4-(2-piridil) piperizinas possuindo actividade agonista do receptor 5ht7
ATE336489T1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
CO5640133A2 (es) Derivados de 4-(2-feniloxifenil)-piperidina o 1,2,3,6-tetrahidropiridina como inhibidores de la recaptacion de la serotonina